当前位置: 首页 >> 检索结果
1. [Non-small cell lung cancer in adults under 40 years of age].
Non-small cell lung cancers (NSCLC) are the most common lung cancers, withpeak incidence at 65years of age. These cancers rarely occur before the age of 40.
2. [The relationship between tumor recurrence and polymorphisms of hGPX1 and NRAMP1 in superficial bladder cancer patients: a meta-analysis].
Previous studies about the relationship between tumor recurrence and NRAMP1 and HGPX1 gene polymorphism in patients with non-muscle-invasive bladder cancer (NMIBC) showed inconsistent results.
3. [Update on molecular classifications and new histological classification of bladder cancer].
Comment the new WHO histological classification of tumors of the urinary system and male genital organs 2016 and expose the state of art about urothelial carcinogenesis and molecular modifications of bladder cancer, with the consequences on the treatments.
4. [Second generation ALK inhibitors in non-small cell lung cancer: systemic review].
作者: Marie Viala.;Solenn Brosseau.;David Planchard.;Benjamin Besse.;Jean-Charles Soria.
来源: Bull Cancer. 2015年102卷4期381-9页
The identification of the EML4-ALK rearrangement in 5% of NSCLC enhanced the development of 1st generation ALK inhibitors such as crizotinib. Two phase III trials demonstrated crizotinib efficacy in second line metastatic (PROFILE 1007) and more recently first line metastatic (PROFILE 1014) NSCLC in terms of progression-free survival and also objective response. However, within 12 to 16 months, patients will progress due to the emergence of acquired resistance mechanisms such as mutation (L1196M) or amplification of the ALK gene, as well as activation of alternative signaling pathways (EGFR, KRAS). Second generation ALK inhibitors have been developed such as ceritinib, alectinib, and AP26113. This review will present those new drugs, summarize the results of their ongoing trials, and discuss the best way to treat ALK+ NSCLC patients.
5. [Pathologic analysis of upper tract urothelial carcinomas: state of the art review for the yearly scientific report of the French National Association of Urology].
Upper tract urothelial carcinomas (UTUC) are rare tumors. Pathologist have a crucial role in establishing the diagnosis and the evaluation of the prognosis of these tumors.
6. [Carcinogenic pathways and natural history of upper tract urothelial carcinomas: state-of-the-art review for the yearly scientific report of the French National Association of Urology].
To describe natural history and carcinogenesis of upper tract urothelial carcinoma (UTUC).
|